Laurus Labs has entered into a strategic partnership agreement with Global Fund for a period of 3.5 years.
Through this long term agreement Laurus Labs will have the volume commitments from the Global Fund for the treatment of HIV/AIDS.
Under this Partnership agreement Laurus Labs received and executed the order from Global Fund which would cater to the supplies of the high burden diseases countries in Sub Saharan African (SSA) region. This is the maiden order for Tenofovir/Lamivudine/Dolutegravir 300/300/50mg (TLD) after the Company received a tentative approval from USFDA in the month of February 2019.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)